Delving into the Latest Updates on KK-R002 with Synapse

Overview

Basic Info

Drug Type

Chemical drugs

Synonyms

KK-R002

Target-

Action-

Mechanism-

Therapeutic Areas

Infectious DiseasesRespiratory Diseases

Active Indication

Community-acquired bacterial pneumonia

Inactive Indication-

Originator Organization

Anhui Kangzheng Kangren Pharmaceutical Co., Ltd.

Active Organization

Anhui Kangzheng Kangyuan Pharmaceutical Co., Ltd.Anhui Kangzheng Kangren Pharmaceutical Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

主要目的：评价在健康成年参与者中单次、多次静脉输注KK-R002后的安全性和耐受性；评价在健康成年参与者中单次、多次静脉输注KK-R002后的药代动力学特征。次要目的：评价KK-R002不同处方配比的药代动力学特征；通过对比单次静脉输注注射用头孢唑林钠、注射用丙磺舒钠和KK-R002后的药代动力学特征，评价KK-R002静脉输注后头孢唑林钠和丙磺舒钠的药物相互作用

[Translation]

Primary purpose: To evaluate the safety and tolerability of KK-R002 after single and multiple intravenous infusions in healthy adult participants; To evaluate the pharmacokinetic characteristics of KK-R002 after single and multiple intravenous infusions in healthy adult participants. Secondary purpose: To evaluate the pharmacokinetic characteristics of KK-R002 with different prescription ratios; To evaluate the drug interaction between cefazolin sodium and probenecid sodium after intravenous infusion of KK-R002 by comparing the pharmacokinetic characteristics of cefazolin sodium for injection, probenecid sodium for injection and KK-R002 after single intravenous infusion

Start Date03 Jul 2025

Sponsor / Collaborator

Anhui Kangzheng Kangren Pharmaceutical Co., Ltd.

[+1]

100 Clinical Results associated with KK-R002

Login to view more data

100 Translational Medicine associated with KK-R002

Login to view more data

100 Patents (Medical) associated with KK-R002

Login to view more data

100 Deals associated with KK-R002

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Community-acquired bacterial pneumonia	Phase 1	China	Anhui Kangzheng Kangyuan Pharmaceutical Co., Ltd.	03 Jul 2025
Community-acquired bacterial pneumonia	Phase 1	China	Anhui Kangzheng Kangren Pharmaceutical Co., Ltd.	03 Jul 2025